Mazdutide Reference

GLP-1 / glucagon dual agonist · Phase 3 investigational (China)

ClassGLP-1 / glucagon dual agonist
StatusPhase 3 investigational (China)
Typical vials5 mg, 10 mg
Dose range2 mg to 6 mg
FrequencyOnce weekly
Half-life~6.5 days
Dosing unitmilligrams
RouteSubcutaneous injection

What Mazdutide is

Mazdutide is a GLP-1 / glucagon dual agonist developed by Innovent and Eli Lilly, furthest along in Chinese Phase 3 trials for obesity and diabetes. It is not FDA approved. Published pharmacokinetic data is thinner than for the other incretins here, so treat the curve as approximate.

Reconstitution math

Concentration is everything: the same 10 mg vial gives a different draw for every amount of bacteriostatic water you add. The table uses the common 2 mL setup for each vial size, which puts every unit on a U-100 insulin syringe at 50 mcg for the default vial. Dashes mark draws too small to measure or larger than the syringe.

VialBAC waterConcentration2 mg4 mg6 mg
5 mg2 mL2.5 mg/mL80 u--
10 mg2 mL5 mg/mL40 u80 u-
Mazdutide syringe drawsDRAW GUIDEEach dose as a filled syringe10 mg vial + 2 mL bacteriostatic water = 0.5 mg per 0.1 mL (10 units).0102030405060708090100units on a U-100 insulin syringe2 mg40 u (0.4 mL)4 mg80 u (0.8 mL)peprecon.com
Draw positions for the common doses at the default setup.

Dosing and protocol

Phase 1b weekly escalation, 6 mg cohort: 2 to 4 to 6 mg.

The Phase 1b escalation stepped 2, then 4, then 6 mg weekly in four-week holds. Higher-dose cohorts (9 and 10 mg) have been studied, but 6 mg is the best-documented maintenance point.

Mazdutide titration scheduleDOSINGThe published escalation, step by stepDose per injection (weekly), from the schedule cited below.0246mg135791113week246maintenancepeprecon.com
Each step is held before escalating; the final dose continues as maintenance.

Pharmacokinetics

Mazdutide has published human pharmacokinetics: published terminal half-life spans a wide range; the curve uses a representative 6.5 days. The curves below are normalized one-compartment models built from the cited half-life, the same math the Planner uses. They show shape and timing, not absolute blood levels.

Mazdutide single-dose curvePHARMACOKINETICSOne dose, start to finishRelative level after one subcutaneous dose. Half-life ~6.5 days; about 97% cleared by 34 days.0%25%50%75%100%0102030days after injectionpeak ~3 dayshalf of peakpeprecon.com
Mazdutide accumulation with weekly dosingPHARMACOKINETICSThe same weekly dose builds for weeksRelative level with the same dose every week. Levels stop climbing around week 5.0%25%50%75%100%012345678weeks on the same weekly dosesteady statemarkers = weekly injectionspeprecon.com
Why week-one effects understate the eventual dose: levels build for weeks.

Storage and handling

Lyophilized vials keep best cold, dark, and dry; refrigeration is the community default and freezing lyophilized powder is common for long holds. After reconstitution, refrigerate at 2 to 8 C, do not freeze the solution, and date the vial. Bacteriostatic water's preservative keeps multi-dose use practical for about 28 days by USP convention, though our 120-day stability study found the preservative itself outlasts that window.

Got a certificate of analysis with your vial? Run it through our COA Reader: it reads the report in plain English, checks purity and mass against the label claim, and links the testing lab’s own verification page. Our guide to reading a COA explains what the numbers do and do not tell you.

Sources

  1. Mazdutide (IBI362) 9 mg / 10 mg Phase 1b, eClinicalMedicine 2022 (PMC9561728)
  2. IBI362 Phase 1b multiple ascending dose study (PMC8374649)

Related references: Survodutide · Retatrutide · Tirzepatide